T-lymphoblast lymphoma is a highly aggressive malignancy that is difficult to treat, has a relatively short course, and has a very high recurrence rate. Therefore, after the diagnosis of T-lymphoblast lymphoma is confirmed, it should be treated immediately and aggressively. The main treatment is usually the application of systemic chemotherapy, which can be given firstly as induction chemotherapy and secondly as intensive consolidation therapy. In addition, some patients can be treated with molecular targeted therapy. For patients who have relapsed after complete remission, or who are at high risk, allogeneic hematopoietic stem cell transplantation is generally recommended as the first-line consolidation therapy. In addition, patients with T-lymphoblast lymphoma, which is prone to central nervous system infiltration, should be examined for cerebrospinal fluid and treated with prophylactic intrathecal drug injections; T-lymphoblast lymphoma is highly malignant and should be treated aggressively for a longer remission.